A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects.
Latest Information Update: 10 Oct 2012
At a glance
- Drugs AZD 2115 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 02 Apr 2012 Planned End Date changed from 1 Mar 2012 to 1 Jun 2012 London as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.